MOTS-c

Research

Mitochondrial ORF of 12S rRNA-c

Aliases
Mitochondrial peptide MOTS-c
Administration
Subcutaneous injection

Research and regulatory

Development stage

Preclinical (mouse models); emerging human research interest.

Legal and regulatory

Unscheduled research compound; not FDA approved. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 7-5 to recommend MOTS-c for the 503A Bulks List, which would make it eligible for pharmacy compounding — this is a recommendation only, not yet legal to compound, pending formal FDA rulemaking.

Side effects

Limited data on human side effects